Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]

  • In development
  • GID-TA11468
  • Expected publication date: 

Documents

Documents created during the development process.

Draft guidance: 1

Declaration of interests

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6388

Topic selection